What is the role of PARP inhibitors in treating Prostate Cancer

PARP Inhibitors in Prostate Cancer Treatment

How PARP Inhibitors Work

PARP inhibitors are a type of targeted therapy that work by blocking an enzyme called PARP (poly [ADP-ribose] polymerase). Think of PARP as a "backup repair crew" for damaged DNA in cells.

Here's the clinical reasoning doctors use:

The DNA Repair System:

• Your cells have primary "proofreaders" called BRCA1 and BRCA2 genes that fix DNA damage
• PARP is a backup system that repairs single-strand DNA breaks
• When PARP is blocked by a PARP inhibitor, single-strand breaks become double-strand breaks
• Cancer cells with BRCA mutations can't repair these double-strand breaks and die
• Normal cells with functioning BRCA genes can still survive because they have a second working copy

According to CancerPatientLab's webinar on "Guiding Personalized Treatment for Advanced Prostate Cancer," the concept is that "you can block the proofreaders inside the cancer cell directly, so that the cancer basically falls apart from overwhelming errors."

Current FDA-Approved PARP Inhibitor Combinations

1. Olaparib + Abiraterone (PROpel Study)

The PROpel study tested this combination in 800 men with metastatic castrate-resistant prostate cancer (mCRPC—cancer that has spread and no longer responds to hormone therapy):

• For patients WITH BRCA mutations: Showed a massive improvement in overall survival with a hazard ratio of 0.2 (meaning dramatically better outcomes)
• For all patients: Delayed progression by approximately 8-11 months
• FDA approval: Approved specifically for patients with BRCA mutations (either inherited or in the tumor)

2. Talazoparib + Enzalutamide (TALAPRO-2 Study)

This newer combination showed:

• Delayed progression by 8-10 months in all patients
• FDA approval: Limited to patients with "DNA repair defects" or homologous recombination deficiency (HRD)
• Patients with BRCA2 mutations showed the greatest benefit
• Important note: Has more anemia risk (43% vs. 16% with olaparib)

Who Benefits Most?

PARP inhibitors are most effective for:

• Patients with germline BRCA1/BRCA2 mutations (inherited mutations you're born with)
• Patients with somatic BRCA mutations (mutations only in the cancer cells)
• Patients with other DNA repair gene mutations (ATM, PALB2)

According to the webinar, patients with BRCA mutations show "a humongous benefit" compared to those without these mutations.

Important Considerations

Benefits:

• Oral medication (taken as pills, not infusions)
• Can delay cancer progression significantly
• Particularly effective for BRCA-positive patients
• May allow breaks from chemotherapy

Side Effects & Risks:

• Anemia (low red blood cell count) - about 1 in 6 patients require blood transfusions
• Fatigue
• Low blood counts requiring careful monitoring
• Rare risk of myelodysplastic syndrome (bone marrow disorder)
• Drug interactions with other medications (for example, enzalutamide reduces olaparib effectiveness)

Important: These are "like chemo pills" and require expert oncology care with careful dose management and blood count monitoring.

Questions to Ask Your Oncologist

1. Have I been tested for BRCA mutations? (Both germline and tumor testing)

   • This is critical because most men in community practices aren't getting this testing

2. If I have a BRCA mutation, why isn't a PARP inhibitor combination being considered for me?

3. What DNA repair gene mutations does my tumor have? (Ask for comprehensive genomic testing)

4. Which PARP inhibitor combination would be best for my specific situation, and why?

   • Different PARP inhibitors have different side effect profiles and drug interactions

5. How will you monitor me for side effects, especially anemia and blood counts?

6. Are there clinical trials available that might include PARP inhibitor combinations?

Key Takeaway

According to CancerPatientLab's expert oncologists, PARP inhibitors represent "the biggest breakthrough" in prostate cancer treatment in recent years, particularly for patients with DNA repair mutations. However, the critical first step is getting tested for BRCA and other DNA repair mutations—something that's unfortunately not happening consistently in many urology practices.

As emphasized in the webinars, "Most men in the community are not getting any testing, especially in rural and urology practices. You should ask your doctor about getting both germline and tumor testing, which can identify potential treatment options for you."

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.